Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma.
Shuichi AokiKoetsu InoueSebastian KleinStefan HalvorsenJiang ChenAya MatsuiMohammad R NikmaneshiShuji KitaharaTai HatoXianfeng ChenKazumichi KawakuboHadi T NiaIvy ChenDaniel H SchanneEmilie MamessierKohei ShigetaHiroto KikuchiRakesh R RamjiawanTyge Ce SchmidtMasaaki IwasakiThomas YauTheodore S HongAlexander QuaasPatrick S PlumSimona DimaIrinel PopescuNabeel BardeesyLance L MunnMitesh J BoradSlim SassiRakesh K JainAndrew X ZhuDan G DudaPublished in: Gut (2021)
PlGF levels were elevated in human ICC stromal cells and circulating blood plasma and were associated with disease progression. Single-cell RNA sequencing showed that the major impact of PlGF blockade in mice was enrichment of quiescent CAFs, characterised by high gene transcription levels related to the Akt pathway, glycolysis and hypoxia signalling. PlGF blockade suppressed Akt phosphorylation and myofibroblast activation in ICC-derived CAFs. PlGF blockade also reduced desmoplasia and tissue stiffness, which resulted in reopening of collapsed tumour vessels and improved blood perfusion, while reducing ICC cell invasion. Moreover, PlGF blockade enhanced the efficacy of standard chemotherapy in mice-bearing ICC. Conclusion PlGF blockade leads to a reduction in intratumorous hypoxia and metastatic dissemination, enhanced chemotherapy sensitivity and increased survival in mice-bearing aggressive ICC.